Iron Chelation and Glucose Metabolism
in [Kidney Diseases]
|
From: ironjustice on 12 Jun 2008 23:55 Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related Articles, Links Comment in: Br J Haematol. 2006 Oct;135(2):271-2. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Haematological Department, Korinthos General Hospital, Korinthos, Greece. Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron-induced endocrinopathies. Starting in January 2001, 42 patients with beta-thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance. PMID: 16822284 [PubMed - indexed for MEDLINE] Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
From: Paul T. Holland on 13 Jun 2008 18:06 bye the bye tom - you do know that this [homozygous beta thalassemia] is a hereditary genetic disorder don't you? thanks for posting it, even if not particularly germane to this group, you see tom, it's one more instance wherein the proven actual cause and effect makes your thesis moot. and you posted it all by yourself... cause and effect tommy - out of your own mouth [figuratively speaking of course] ironjustice wrote: > > Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related > Articles, Links > Comment in: > Br J Haematol. 2006 Oct;135(2):271-2. > > Effect of enhanced iron chelation therapy on glucose metabolism in > patients with beta-thalassaemia major. > > Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, > Tolis G. > > Haematological Department, Korinthos General Hospital, Korinthos, > Greece. > > Recently introduced chelation regimens that combine deferoxamine (DFO) > and deferiprone have been shown to have greater efficacy in promoting > iron excretion than either chelator alone and have been associated > with rapid reduction of the iron load in the heart and liver, and with > reversal of cardiac dysfunction. It is unclear whether this combined > therapy could be associated with a reduction in iron load or decline > in the severity of iron-induced endocrinopathies. Starting in January > 2001, 42 patients with beta-thalassaemia major, previously maintained > on subcutaneous DFO only, were switched to combined treatment with DFO > and deferiprone. The primary endpoint was to investigate the effects > of this therapy on the glucose metabolism characteristics of this > population. Combination therapy markedly decreased ferritin levels > (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose > responses were improved at all times during an oral glucose tolerance > test, particularly in patients in early stages of glucose intolerance. > Glucose quantitative secretion also decreased significantly with > combined therapy, while no significant change occurred in insulin > levels in any group. Insulin secretion, according to the homeostasis > assessment model, markedly increased in all groups, while overall > reduction in insulin sensitivity did not reach statistical > significance. This study showed that the combination of DFO and > deferiprone was associated with an improvement in liver iron > deposition and glucose intolerance. > > PMID: 16822284 [PubMed - indexed for MEDLINE] > > Who loves ya. > Tom > > Jesus Was A Vegetarian! > http://tinyurl.com/2r2nkh > > Man Is A Herbivore! > http://tinyurl.com/a3cc3 > > DEAD PEOPLE WALKING > http://tinyurl.com/zk9fk
From: J666 on 13 Jun 2008 18:32 On Fri, 13 Jun 2008 17:06:48 -0500, Paul T. Holland wrote (in article <4852F09F.CD086147(a)bellatlantic.net>): > cause and effect tommy - out of your own mouth [figuratively speaking of > course] And so his words are only worth a FARThing.
From: ironjustice on 13 Jun 2008 19:39 On Jun 13, 3:06 pm, "Paul T. Holland" <pholl...(a)bellatlantic.net> wrote:long winded whack << Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related Articles, Links Comment in: Br J Haematol. 2006 Oct;135(2):271-2. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Haematological Department, Korinthos General Hospital, Korinthos, Greece. Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron-induced endocrinopathies. Starting in January 2001, 42 patients with beta-thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance. PMID: 16822284 [PubMed - indexed for MEDLINE] Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
From: ironjustice on 13 Jun 2008 19:41 On Jun 13, 3:32 pm, J666 <j...(a)nowhere.com> wrote: how many different bacteria in sht << Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related Articles, Links Comment in: Br J Haematol. 2006 Oct;135(2):271-2. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Haematological Department, Korinthos General Hospital, Korinthos, Greece. Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron-induced endocrinopathies. Starting in January 2001, 42 patients with beta-thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance. PMID: 16822284 [PubMed - indexed for MEDLINE] Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
|
Next
|
Last
Pages: 1 2 3 Prev: Kidney Foundation Drops Fluoride Support Next: Smoke and Transplants |